Pandorum Technologies raised US$18 million in Series B funding to advance programmable tissue regenerative therapies.
- Amount
- $18M
- Stage
- Series B
- Announced
- 9 February 2026
- Lead
- Protons Corporate
- Other investors
- Galentic Pharma, Ashish Kacholia, Noblevast Advisory, Avinya Fund, Burman Family
- Use of funds
- Clinical development of exosome-based therapies, global manufacturing scale-up, and operations in the U.S., Japan, and Middle East.
- Checked
- Amount and date matched across 3 press sources